244 related articles for article (PubMed ID: 29642081)
61. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
62. High-Contrast CXCR4-Targeted
Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
[TBL] [Abstract][Full Text] [Related]
63. Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors.
Weich A; Serfling SE; Schlötelburg W; Higuchi T; Hartrampf PE; Schirbel A; Heinrich M; Buck AK; Rowe SP; Kosmala A; Werner RA
Clin Nucl Med; 2023 Jul; 48(7):586-593. PubMed ID: 37167408
[TBL] [Abstract][Full Text] [Related]
64.
Kraus S; Dierks A; Rasche L; Kertels O; Kircher M; Schirbel A; Zovko J; Steinbrunn T; Tibes R; Wester HJ; Buck AK; Einsele H; Kortüm KM; Rosenwald A; Lapa C
J Nucl Med; 2022 Jan; 63(1):96-99. PubMed ID: 34049979
[TBL] [Abstract][Full Text] [Related]
65. 68 Ga-Pentixafor PET/CT for in-vivo mapping of CXCR4 receptors as potential radiotheranostic targets in soft tissue and bone sarcoma: preliminary results.
Jena SR; Watts A; Aggarwal P; Bachhal V; Kaur H; Dhingra K; Singh H; Bal A; Singh B
Nucl Med Commun; 2024 Mar; 45(3):229-235. PubMed ID: 38165171
[TBL] [Abstract][Full Text] [Related]
66. [(68)Ga]Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression After Myocardial Infarction.
Lapa C; Reiter T; Werner RA; Ertl G; Wester HJ; Buck AK; Bauer WR; Herrmann K
JACC Cardiovasc Imaging; 2015 Dec; 8(12):1466-1468. PubMed ID: 26699115
[No Abstract] [Full Text] [Related]
67. Accuracy of PET quantification in [
Rausch I; Beitzke D; Li X; Pfaff S; Rasul S; Haug AR; Mayerhoefer ME; Hacker M; Beyer T; Cal-González J
J Nucl Cardiol; 2022 Apr; 29(2):492-502. PubMed ID: 32696137
[TBL] [Abstract][Full Text] [Related]
68. [Preliminary study on the ability of
Gao YJ; Ding J; Cui YY; Li TY; Zhang YS; Huo L; Tong AL
Zhonghua Nei Ke Za Zhi; 2023 Mar; 62(3):267-271. PubMed ID: 36822852
[No Abstract] [Full Text] [Related]
69. PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study.
Wang H; Hou B; Lu L; Feng M; Zang J; Yao S; Feng F; Wang R; Li F; Zhu Z
J Nucl Med; 2018 Mar; 59(3):523-528. PubMed ID: 28775202
[TBL] [Abstract][Full Text] [Related]
70. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
71. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.
Wester HJ; Keller U; Schottelius M; Beer A; Philipp-Abbrederis K; Hoffmann F; Šimeček J; Gerngross C; Lassmann M; Herrmann K; Pellegata N; Rudelius M; Kessler H; Schwaiger M
Theranostics; 2015; 5(6):618-30. PubMed ID: 25825601
[TBL] [Abstract][Full Text] [Related]
72. CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma.
Herhaus P; Lipkova J; Lammer F; Yakushev I; Vag T; Slotta-Huspenina J; Habringer S; Lapa C; Pukrop T; Hellwig D; Wiestler B; Buck AK; Deckert M; Wester HJ; Bassermann F; Schwaiger M; Weber W; Menze B; Keller U
J Nucl Med; 2020 Dec; 61(12):1765-1771. PubMed ID: 32332145
[TBL] [Abstract][Full Text] [Related]
73. CXCR4 Expression Demonstrated by 68Ga-Pentixafor PET/CT Imaging in a Case of Systemic Mastocytosis Mimicking Lymphoma.
Kiran MY; Apaydin Arikan E; Sanli Y; Yegen G; Kuyumcu S
Clin Nucl Med; 2021 Dec; 46(12):e563-e564. PubMed ID: 34269725
[TBL] [Abstract][Full Text] [Related]
74. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.
Chen Z; Xue Q; Yao S
Mini Rev Med Chem; 2023; 23(7):787-803. PubMed ID: 36529918
[TBL] [Abstract][Full Text] [Related]
75. Chemokine Receptor 4-Targeted PET/CT With 68 Ga-Pentixather Detects More Lesions Than 68 Ga-Pentixafor PET/CT in Multiple Myeloma.
Yang Q; Zhang F; Hao Z; Zhuang J; Huo L
Clin Nucl Med; 2024 Jun; 49(6):592-593. PubMed ID: 38630995
[TBL] [Abstract][Full Text] [Related]
76. Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo - a comparison to [(68)Ga]pentixafor.
Poschenrieder A; Schottelius M; Schwaiger M; Wester HJ
EJNMMI Res; 2016 Dec; 6(1):70. PubMed ID: 27655427
[TBL] [Abstract][Full Text] [Related]
77. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas.
Weich A; Werner RA; Buck AK; Hartrampf PE; Serfling SE; Scheurlen M; Wester HJ; Meining A; Kircher S; Higuchi T; Pomper MG; Rowe SP; Lapa C; Kircher M
Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33805264
[TBL] [Abstract][Full Text] [Related]
78. Molecular Imaging of Chemokine Receptor CXCR4 in Non-Small Cell Lung Cancer Using 68Ga-Pentixafor PET/CT: Comparison With 18F-FDG.
Derlin T; Jonigk D; Bauersachs J; Bengel FM
Clin Nucl Med; 2016 Apr; 41(4):e204-5. PubMed ID: 26756098
[TBL] [Abstract][Full Text] [Related]
79. Considerations on PET/MR imaging of carotid plaque inflammation with
Toczek J; Riou L
J Nucl Cardiol; 2022 Apr; 29(2):503-505. PubMed ID: 32914318
[No Abstract] [Full Text] [Related]
80. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]